+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Glucagon Like Peptide 2 Receptor - Pipeline Review, H2 2020

  • PDF Icon

    Drug Pipelines

  • 67 Pages
  • November 2020
  • Region: Global
  • Global Markets Direct
  • ID: 5229527
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

Glucagon Like Peptide 2 Receptor (GLP2R) - Glucagon-like peptide 2 receptor (GLP-2R) is a protein encoded by the GLP2R gene. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut. GLP2 stimulates intestinal growth and up regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. GLP2 prevents intestinal hypoplasia resulting from total parenteral nutrition.

Glucagon Like Peptide 2 Receptor (GLP2R) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 3, 5, 1 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Gastrointestinal, Immunology, Musculoskeletal Disorders, Other Diseases and Undisclosed which include indications Short Bowel Syndrome, Crohn's Disease (Regional Enteritis), Inflammation, Multiple Organ Failure (Multiple Organ Dysfunction Syndrome), Osteoporosis and Unspecified Rare Disease.

The latest report Glucagon Like Peptide 2 Receptor - Pipeline Review, H2 2020, outlays comprehensive information on the Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Glucagon Like Peptide 2 Receptor (GLP2R)
  • The report reviews Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics

Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glucagon Like Peptide 2 Receptor (GLP2R)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glucagon Like Peptide 2 Receptor (GLP2R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

IntroductionGlucagon Like Peptide 2 Receptor (GLP2R) - Overview
Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes

Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Glucagon Like Peptide 2 Receptor (GLP2R) - Companies Involved in Therapeutics Development
9 Meters Biopharma Inc
  • Bainan Biotech ApS
  • Hanmi Pharmaceuticals Co Ltd
  • Huons Global Co Ltd
  • OPKO Health Inc
  • PhaseBio Pharmaceuticals Inc
  • Sosei Heptares
  • Takeda Pharmaceutical Co Ltd
  • Tasly Pharmaceutical Group Co Ltd
  • VectivBio Holding AG
  • Zealand Pharma AS

Glucagon Like Peptide 2 Receptor (GLP2R) - Drug Profiles
apraglutide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Drugs to Agonize GIP and GLP-2 for Osteoporosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Fusion Protein to Agonize GLP2R for Short Bowel Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

glepaglutide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

GXG-8 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

HL-06 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

HM-15912 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

MOD-1501 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

NB-1002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

NM-003 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Peptide to Agonize GLP2R for Intestinal Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

teduglutide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

teduglutide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

ZP-7570 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Glucagon Like Peptide 2 Receptor (GLP2R) - Dormant Products

Glucagon Like Peptide 2 Receptor (GLP2R) - Discontinued Products
Glucagon Like Peptide 2 Receptor (GLP2R) - Product Development Milestones
  • Featured News & Press Releases
  • Jul 01, 2020: Hanmi Pharm’s short-bowel syndrome drug wins FDA’s rare pediatric disease status
  • Feb 10, 2020: The Scottish Medicines Consortium advises on newly licensed medicine Revestive for use by NHSScotland
  • Jun 26, 2019: Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome
  • May 17, 2019: Therachon to present data from ongoing Phase II Study of Apraglutide for Short Bowel Syndrome at Digestive Disease Week
  • May 17, 2019: U.S. FDA approves GATTEX (teduglutide) for children 1 year of age and older with Short Bowel Syndrome
  • May 07, 2019: Zealand Pharma enrolls first patient in Phase 3 extension study of glepaglutide for treatment for short bowel syndrome
  • May 03, 2019: Hanmi's short bowel syndrome treatment becomes orphan drug in US
  • Mar 25, 2019: Therachon presents data from preclinical and phase I clinical studies of Apraglutide for the treatment of Short Bowel Syndrome at ASPEN 2019 Nutrition Science & Practice Conference
  • Feb 05, 2019: Pharm-Olam enrolls patients in Zealand Pharma orphan drug study
  • Jan 16, 2019: Therachon is granted Orphan Drug Designation by US FDA for Apraglutide for the treatment of Short Bowel Syndrome
  • Nov 29, 2018: Therachon is granted Orphan Drug Designation in the European Union for apraglutide for the treatment of short bowel syndrome
  • Nov 13, 2018: U.S. FDA accepts for filing Shire's supplemental New Drug Application for GATTEX (teduglutide [rDNA origin]) for children with Short Bowel Syndrome
  • Oct 05, 2018: Zealand Pharma enrols first patient in Phase lll study of glepaglutide
  • May 31, 2018: Zealand Pharma to present new clinical Phase 2 results on glepaglutide for the treatment of short bowel syndrome at the DDW conference in the U.S.
  • Apr 26, 2018: Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome

Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer

List of Tables
  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indication, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products under Investigation by Universities/Institutes, H2 2020
  • Products under Investigation by Universities/Institutes, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by 9 Meters Biopharma Inc, H2 2020
  • Pipeline by Bainan Biotech ApS, H2 2020
  • Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2020
  • Pipeline by Huons Global Co Ltd, H2 2020
  • Pipeline by OPKO Health Inc, H2 2020
  • Pipeline by PhaseBio Pharmaceuticals Inc, H2 2020
  • Pipeline by Sosei Heptares, H2 2020
  • Pipeline by Takeda Pharmaceutical Co Ltd, H2 2020
  • Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2020
  • Pipeline by VectivBio Holding AG, H2 2020
  • Pipeline by Zealand Pharma AS, H2 2020
  • Dormant Projects, H2 2020
  • Discontinued Products, H2 2020

List of Figures
  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020

Companies Mentioned

A selection of companies mentioned in this report includes:

  • 9 Meters Biopharma Inc
  • Bainan Biotech ApS
  • Hanmi Pharmaceuticals Co Ltd
  • Huons Global Co Ltd
  • OPKO Health Inc
  • PhaseBio Pharmaceuticals Inc
  • Sosei Heptares
  • Takeda Pharmaceutical Co Ltd
  • Tasly Pharmaceutical Group Co Ltd
  • VectivBio Holding AG
  • Zealand Pharma AS